IMUNON, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9131 USD | +1.68% |
|
+1.47% | -3.88% |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Oncology Drug Development | 500K | 500K | 500K | 500K | - | |||||
Total Assets | 38.28M | 37.53M | 74.05M | 43.98M | 21.92M | |||||
Interest Expense | -1.39M | -1.29M | -570K | -5.03M | -197K | |||||
Income Tax Expense | -1.82M | -1.85M | -1.38M | -1.57M | -1.28M | |||||
CAPEX | -349K | -19.09K | -312K | -268K | -452K | |||||
EBT | -18.67M | -23.33M | -22.15M | -37.47M | -20.8M | |||||
D&A | 722K | 742K | 703K | 732K | 720K | |||||
Operating Income | -20.57M | -18.49M | -21.01M | -24.92M | -21.03M | |||||
Net Income | -16.85M | -21.48M | -20.77M | -35.9M | -19.51M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 500K | 500K | 500K | 500K | - | |||||
Total Assets | 38.28M | 37.53M | 74.05M | 43.98M | 21.92M | |||||
Interest Expense | -1.39M | -1.29M | -570K | -5.03M | -197K | |||||
Income Tax Expense | -1.82M | -1.85M | -1.38M | -1.57M | -1.28M | |||||
D&A | 722K | 742K | 703K | 732K | 720K | |||||
CAPEX | -349K | -19.09K | -312K | -268K | -452K | |||||
Net Income | -16.85M | -21.48M | -20.77M | -35.9M | -19.51M | |||||
EBT | -18.67M | -23.33M | -22.15M | -37.47M | -20.8M | |||||
Operating Income | -20.57M | -18.49M | -21.01M | -24.92M | -21.03M |
- Stock Market
- Equities
- IMNN Stock
- Financials Imunon, Inc.
- Business Segments